【摘要】 目的　观察联合用药对慢性乙型肝炎（Ｃｈｒｏｎｉｃ Ｈｅｐａｔｉｔｉｓ Ｂ ＣＨＢ） 的治疗效果。方法　６８ 例ＣＨＢ 患者随机分为３ 组，干扰素联合无环鸟苷组：α－ 干扰素３００ 万ｉｕ 肌注、隔日一次，同时口服无环鸟苷，每次０－４ｇ ，每日３ 次，疗程３ 个月，甘力欣联合猪苓多糖组：甘力欣５０ ｍｌ ，静点，每天１ 次，猪苓多糖，肌注，每天１ 次，３ 个月为一个疗程；对照组：予一般护肝治疗。疗程结束检测乙肝病毒标致物。结果　α－ 干扰素组与对照组比较，甘力欣组与对照组比较ＨＢｅＡｇ 、ＨＢＶ－ＤＮＡ 阴转率有显著性差异（Ｐ＜ ０－０５） ；α－ 干扰素组与甘力欣组比较ＨＢｅＡｇ 、ＨＢＶ－ ＤＮＡ 阴转率无显著性差异（Ｐ＞ ０－０５） 。结论　干扰素联合无环鸟苷、甘力欣联合猪苓多糖对ＨＢｅＡｇ 、ＨＢＶ－ ＤＮＡ 阴转有较好疗效更多还原

【Abstract】 Aim To explore the Combination Interferon and Aciclovir in the Treatment of Chronic Hepatitis B(CHB).Method 68 cases diagnosed as CHB were divided into 3 groups randomly Combination Interferon and Aciclovir,Combination Diammonium glycyrrhizinate and polyporus and the control group with routine liver protective drugs orally.Results The clearance rates of HBeAg and HBV DNA in the Interferon and Diammonium glycyrrhizinate group were 63.2% and 55.6%,50.0% and 42.1%respectively,Compared with the control,the clearance rates have significant difference (P<0.05),there were no significant difference between Interferon and Diammonium glycyrrhizinate groups.Conclusion Combination Interferon and Aciclovir,Combination Diammonium glycyrrhizinate and polyporus have a good clearance rates of HBeAg and HBV DNA on the CHB patients.更多还原